References
Taken K, Aslan R, Eryilmaz R, Alp HH, Huyut Z, Donmez MI (2022) Serum irisin is a novel biomarker for bladder cancer detection. Int Urol Nephrol 54(1):55–61. https://doi.org/10.1007/s11255-021-03074-4
Kawada T (2022) Serum irisin concentration in patients with bladder cancer. Int Urol Nephrol. https://doi.org/10.1007/s11255-022-03199-0
Esawy MM, Abdel-Samd KM (2020) The diagnostic and prognostic roles of serum irisin in bladder cancer. Curr Probl Cancer 44(4):100529. https://doi.org/10.1016/j.currproblcancer.2019.100529
Kinn Rod AM, Harkestad N, Jellestad FK, Murison R (2017) Comparison of commercial ELISA assays for quantification of corticosterone in serum. Sci Rep 7(1):6748. https://doi.org/10.1038/s41598-017-06006-4
Kim JS, Galvao DA, Newton RU, Gray E, Taaffe DR (2021) Exercise-induced myokines and their effect on prostate cancer. Nat Rev Urol 18(9):519–542. https://doi.org/10.1038/s41585-021-00476-y
Tsiani E, Tsakiridis N, Kouvelioti R, Jaglanian A, Klentrou P (2021) Current evidence of the role of the myokine irisin in cancer. Cancers (Basel). https://doi.org/10.3390/cancers13112628
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical approval
This letter does not contain any studies with human participants or animals performed by the author.
Informed consent
There is no need of informed consent in this letter.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Taken, K., Aslan, R., Eryilmaz, R. et al. Response to Letter to the Editor ‘Serum irisin concentration in patients with bladder cancer’. Int Urol Nephrol 54, 1247–1248 (2022). https://doi.org/10.1007/s11255-022-03215-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-022-03215-3